ZOETIS INC (ZTS) Stock News
NYSE:ZTS - New York Stock Exchange, Inc. - US98978V1035 - Common Stock - Currency: USD
ZTS Latest News, Press Relases and Analysis
1 Safe-and-Steady Stock to Target This Week and 2 to Be Wary Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
Zoetis (ZTS) concluded the recent trading session at $156.40, signifying a +0.62% move from its prior day's close.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CPRX
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: NBIX
Zoetis (ZTS) Advances But Underperforms Market: Key Facts
In the most recent trading session, Zoetis (ZTS) closed at $152.30, indicating a +0.92% shift from the previous trading day.
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
3 Growth Stocks Down 30% or More to Buy Right Now
Pinpointing strong bargains in the stock market is key to success, and the market is full of them right now. Three companies that are down more than 30% from their all-time highs and look like excellent buys are Nvidia (NASDAQ: NVDA), Taiwan Semiconductor (NYSE: TSM), and ASML (NASDAQ: ASML). As a quick overview of the supply chain, Nvidia places Taiwan Semiconductor's chips in its GPUs (graphics processing units), which have been the primary computing unit deployed by the AI hyperscalers.
Is Archer Aviation Stock a Millionaire Maker?
Archer Aviation (NYSE: ACHR) has built a futuristic airplane that can now be seen buzzing around test sites. Here's what you need to know if you are looking at Archer Aviation today. When digging into the story of Archer Aviation, you have to step back and give the company some respect.
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio. With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
Zoetis (NYSE: ZTS) is a leading animal healthcare company offering over 300 medicines, vaccines, and other precision health products to care for companion animals and livestock globally. Since its spin-off from Pfizer in 2013, Zoetis has delivered an annualized total return of 15%, demonstrating the market-beating potential of what might look like a steady-Eddie investment at first glance. Following this decline, though, Zoetis now trades at a price-to-earnings (P/E) ratio of 27 -- its lowest mark in a decade.
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administration. Zoetis (NYSE: ZTS) is a global leader in animal health, with an extensive portfolio of medicines, vaccines, and diagnostic products for livestock and pets. The company's diversification, covering 17 products generating over $100 million in annual revenue, including several best-in-class treatments, underscores its appeal as an investment.
Zoetis (ZTS) Stock Moves -1.16%: What You Should Know
The latest trading day saw Zoetis (ZTS) settling at $163.11, representing a -1.16% change from its previous close.
4 Top Tech Stocks to Buy Right Now
Amidst the market volatility due to tariffs and trade tensions, many top tech companies are now selling at much more attractive valuations than just a few months ago. Pinterest (NYSE: PINS) operates an online vision board that has more than 550 million monthly active users (MAU) across the globe. Better monetizing its user base is a huge opportunity for Pinterest, especially in the markets outside the U.S. and Europe where more than half its user base resides.
2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 to Be Wary Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Zoetis Inc. (ZTS): Among Stocks with Buy Ratings that Hedge Funds Love
We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a look at where Zoetis Inc. (NYSE:ZTS) stands against other stocks with buy ratings that hedge funds love. The U.S. stock market has been in chaos ever since President Trump announced his […]
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
Zoetis (ZTS): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Zoetis’s shares (currently trading at $166) have posted a disappointing 9.6% loss, well below the S&P 500’s 7.6% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Mentions: PFE